Michele Rusca
Overview
Explore the profile of Michele Rusca including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
560
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bersanelli M, Gnetti L, Pilato F, Varotti E, Quaini F, Campanini N, et al.
Explor Target Antitumor Ther
. 2023 Sep;
4(4):743-756.
PMID: 37720351
Aim: In renal cell carcinoma (RCC), tumor heterogeneity generated challenges to biomarker development and therapeutic management, often becoming responsible for primary and acquired drug resistance. This study aimed to assess...
2.
Cardillo G, Nosotti M, Scarci M, Torre M, Alloisio M, Benvenuti M, et al.
J Thorac Dis
. 2022 Nov;
14(10):3842-3853.
PMID: 36389328
Background: Persistent air leak and the management of intraoperative blood loss are common threats in thoracic surgical practice. The availability of new procedures, technology and materials is constantly evolving topical...
3.
Spaggiari L, Bertolaccini L, Facciolo F, Gallina F, Rea F, Schiavon M, et al.
Lung Cancer
. 2021 Feb;
154:29-35.
PMID: 33610120
Backgrounds: Oligometastatic Non-Small Cell Lung Cancer (NSCLC) patients represent a category without a standard therapeutic approach. However, in selected oligometastatic NSCLC, radical surgery seems to offer a good prognosis. This...
4.
Ventura L, Carbognani P, Gnetti L, Rossi M, Tiseo M, Silini E, et al.
Tumori
. 2020 Jun;
107(3):196-203.
PMID: 32578517
Objective: Currently, unlike earlier years, patients affected by multiple primary malignancies (MPM) are significantly increased, thus representing a clinical-pathologic category worthy of attention. Their clinical features and prognosis still need...
5.
Bocchialini G, Lagrasta C, Madeddu D, Mazzaschi G, Marturano D, Sogni F, et al.
Eur J Cardiothorac Surg
. 2020 Apr;
58(3):619-628.
PMID: 32267920
Objectives: Tumour-infiltrating lymphocytes (TILs) are critically implicated in the clinical outcome and response to immunotherapy in non-small-cell lung cancer (NSCLC) patients. The functional competence of lymphocyte subpopulations is strongly conditioned...
6.
Ventura L, Scarlattei M, Gnetti L, Silini E, Rossi M, Tiseo M, et al.
Tumori
. 2020 Feb;
:300891620904404.
PMID: 32056506
Objective: To evaluate the prognostic role of maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) measured by FDG-positron emission tomography (PET)/computed tomography (CT) in...
7.
Bersanelli M, Gnetti L, Varotti E, Ampollini L, Carbognani P, Leonardi F, et al.
Immunotherapy
. 2019 Feb;
11(1):21-35.
PMID: 30702014
Aim: The knowledge of the immune context of renal cell carcinoma (RCC) is useful to predict benefit from immunotherapy. We retrospectively characterized the immune context of RCC patients underwent primary...
8.
9.
Braggio C, Bocchialini G, Ventura L, Carbognani P, Rusca M, Ampollini L
Acta Biomed
. 2018 Oct;
89(3):408-410.
PMID: 30333468
Black hairy tongue (BHT) is a self-limiting disorder characterized by abnormal hypertrophy and elongation of filiform papillae on the surface of the tongue. The exact mechanism of drug-induced BHT is...
10.
Sonvico F, Barbieri S, Colombo P, Barocelli E, Mucchino C, Cantoni A, et al.
Eur J Pharm Sci
. 2018 Jul;
123:89-97.
PMID: 30030099
Malignant pleural mesothelioma (MPM) is a rare malignancy characterized by a long latency period of 20-50 years after exposure to the main aetiology agent that is asbestos. MPM treatments include...